News - Boxer Capital Makes Significant Investment in Vir Biotechnology with Large Share Purchase

In a significant financial move, Boxer Capital Management disclosed the acquisition of 1,241,000 shares of Vir Biotechnology on May 15, 2026, a deal valued at approximately $9.89 million based on quarterly average pricing. This investment underscores a notable confidence in Vir Biotechnology, which has experienced an impressive 100% increase in its stock value over the past year, outpacing the broader S&P 500 increase of approximately 25%. According to a Securities and Exchange Commission (SEC) filing, this acquisition elevates Boxer Capital's stake in Vir Biotechnology to 2.2% of its reportable assets under management as of March 31, 2026. The company is reported to have bolstered its position in Vir's portfolio due to promising developments and strategic partnerships. Vir Biotechnology is a San Francisco-based company specializing in cutting-edge immunology-based therapies targeting critical infectious diseases, including COVID-19, hepatitis B, influenza A, and HIV. The firm generates revenue through a triad of product sales, strategic licensing agreements, and collaborative research initiatives with global pharmaceutical and biotechnology leaders. The recent surge in Vir Biotechnology's stock is fueled by several promising advancements. Notably, Vir recently presented encouraging Phase 2 trial results for chronic hepatitis delta, where a striking 88% of patients maintained undetectable virus levels through Week 96 using its groundbreaking combination therapy. The company also secured a significant collaboration with Astellas to enhance its prostate cancer therapy, VIR-5500, with key Phase 3 trials slated for 2027. Financially robust, Vir Biotechnology closed the quarter with over $809 million in cash and investments, excluding an additional $315 million from its Astellas partnership expected by the second quarter. Boxer Capital's decisive action indicates a strategic confidence in Vir's capacity to transform its existing cash reserves and extensive research pipeline into a sustainable and commercially viable business model. However, the challenge remains for Vir to maintain momentum and translate scientific breakthroughs into sustained market success before investor optimism wanes.